Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Weill Cornell Uptown CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Weill Cornell Uptown CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Rochester Adult HIV Therapeutic Strategies Network CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Chapel Hill CRS
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Duke University Medical Center CRS
mi
from
Durham, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Duke University Medical Center CRS
mi
from
Durham, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Greensboro CRS
mi
from
Greensboro, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS
mi
from
Greensboro, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Medical Center CRS
mi
from
Winston-Salem, NC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Medical Center CRS
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Clinical Research Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Case Clinical Research Site
mi
from
Cleveland, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Case Clinical Research Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Ohio State University CRS
mi
from
Columbus, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Ohio State University CRS
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Division of Infectious Diseases Clinical Research Center- Drexel University CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina: Division of Infectious Diseases CRS
mi
from
Charleston, SC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina: Division of Infectious Diseases CRS
mi
from
Charleston, SC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics (VT) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Trinity Health and Wellness Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Dallas VA Medical Center CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Dallas VA Medical Center CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
UT Southwestern HIV/ID Clinical Trials Unit CRS
mi
from
Dallas, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
UT Southwestern HIV/ID Clinical Trials Unit CRS
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Michael E. DeBakey VAMC REPRIEVE CRS
mi
from
Houston, TX
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Michael E. DeBakey VAMC REPRIEVE CRS
mi
from
Houston, TX
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University CRS
mi
from
Richmond, VA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University CRS
mi
from
Richmond, VA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Medical College of Wisconsin, Inc. CRS
mi
from
Milwaukee, WI
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Medical College of Wisconsin, Inc. CRS
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Cooper Univ. Hosp. CRS
mi
from
Camden, NJ
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Cooper Univ. Hosp. CRS
mi
from
Camden, NJ
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital CRS
mi
from
Minneapolis, MN
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital CRS
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Oklahoma State University Center for Health Sciences CRS
mi
from
Tulsa, OK
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Oklahoma State University Center for Health Sciences CRS
mi
from
Tulsa, OK
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mills Clinical Research CRS
mi
from
Los Angeles, CA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mills Clinical Research CRS
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Tufts Medical Center CRS
mi
from
Boston, MA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Tufts Medical Center CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Positive Health Clinic CRS
mi
from
Pittsburgh, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Positive Health Clinic CRS
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Toledo Medical Center CRS
mi
from
Toledo, OH
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Toledo Medical Center CRS
mi
from
Toledo, OH
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Community AIDS Network/Comprehensive Care Clinic CRS
mi
from
Sarasota, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Community AIDS Network/Comprehensive Care Clinic CRS
mi
from
Sarasota, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
mi
from
Philadelphia, PA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Center of Translational AIDS Research, Lewis Katz School of Medicine at Temple University CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Inova Heart and Vascular Institute CRS
mi
from
Falls Church, VA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Inova Heart and Vascular Institute CRS
mi
from
Falls Church, VA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai West Samuels CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai West Samuels CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
mi
from
New York, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Infectious Disease Clinical and Translational Research Center (CTRC) CRS
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Arizona CRS
mi
from
Tucson, AZ
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Arizona CRS
mi
from
Tucson, AZ
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Gaborone CRS
mi
from
Gaborone,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Gaborone CRS
mi
from
Gaborone,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
mi
from
Miami, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
University of Miami Infectious Disease Research Unit at Jackson Memorial Hospital CRS
mi
from
Miami, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Malcom Randall VA Medical Center CRS
mi
from
Gainesville, FL
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Malcom Randall VA Medical Center CRS
mi
from
Gainesville, FL
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Washington University Therapeutics (WT) CRS
mi
from
Saint Louis, MO
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Washington University Therapeutics (WT) CRS
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Palmetto Health Clinical Trial Department CRS
mi
from
Columbia, SC
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Palmetto Health Clinical Trial Department CRS
mi
from
Columbia, SC
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Augusta University Research Institute, Inc. CRS
mi
from
Augusta, GA
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Augusta University Research Institute, Inc. CRS
mi
from
Augusta, GA
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Whitman-Walker Health CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Whitman-Walker Health CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Georgetown University CRS (GU CRS)
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Georgetown University CRS (GU CRS)
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Capital Medical Associates, PC CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Capital Medical Associates, PC CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
mi
from
Washington,
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
Infectious Diseases Clinic, Washington DC Veterans Affairs Medical Center CRS
mi
from
Washington,
Click here to add this to my saved trials
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated:  12/31/1969
James J Peters VA Medical Center CRS
mi
from
Bronx, NY
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)
Status: Enrolling
Updated: 12/31/1969
James J Peters VA Medical Center CRS
mi
from
Bronx, NY
Click here to add this to my saved trials
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Inflammation and Coronary Endothelial Function
Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Inflammation and Coronary Endothelial Function
Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute
mi
from
Torrance, CA
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute
mi
from
Torrance, CA
Click here to add this to my saved trials